Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.

@article{Bnhegyi2012Week9E,
  title={Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.},
  author={D{\'e}nes B{\'a}nhegyi and Christine Katlama and Cl{\'o}vis Arns da Cunha and Stefan Werner Schneider and Anita Rachlis and Cassy Workman and Sandra De Meyer and Ann Vandevoorde and Tom van de Casteele and Frank L. Tomaka},
  journal={Current HIV research},
  year={2012},
  volume={10 2},
  pages={
          171-81
        }
}
Long-term potent activity of antiretrovirals is essential for HIV-1-infected, treatment-experienced patients. TITAN (TMC114/r In Treatment-experienced pAtients Naive to lopinavir) compared Week-96 efficacy and safety of darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r). Treatment-experienced, LPV-naive, HIV-1-infected patients were randomised to DRV/r 600/100 mg bid or LPV/r 400/100 mg bid plus optimised background regimen (≥ 2 NRTIs/NNRTIs). 595 patients were enrolled (mean… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Darunavir: A Review of Its Use in the Management of HIV-1 Infection

  • Drugs
  • 2013
VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2018
VIEW 1 EXCERPT

Pharmacokinetic Interactions Between Quinine and Lopinavir/Ritonavir in Healthy Thai Adults.

  • The American journal of tropical medicine and hygiene
  • 2015
VIEW 1 EXCERPT
CITES RESULTS

Similar Papers